Teva's recalled migraine medicine Zecuity has a long local history - Philadelphia Business Journal
USFDA: Teva Pharmaceutical recalls 38,858 bottles of drugs made by Emcure Pharmaceuticals in US market - The Economic Times
More Blood Pressure Drugs Recalled Due to Potential Cancer Risk | Moffitt
Report: Two more blood pressure drugs recalled for potential cancer risk
Teva Recalls One Lot Of IDArubicin Hydrochloride Injection
Recall Issued After Depression Medication And Erectile Dysfunction Drug End Up 'Inadvertently Packaged Together' - CBS Pittsburgh
FDA recall expands for heart drug with possible cancer-causing impurity
Teva recalls US-made drugs following contamination fears - The Boston Globe
Teva Pharmaceuticals USA recalls Losartan Potassium 25mg and 100mg Tablets USP sold exclusively to Golden State Medical Supply - Pharmaceutical Business review
Drug Recall Guide | What to Do If Your Drug Is Recalled
Blood Pressure Medication Recall Expands Over Cancer Risk - SlashGear
/cloudfront-us-east-1.images.arcpublishing.com/gray/VDJXG527L5PCRMIMRGNLUVYPMQ.jpg "New, voluntary recall issued for popular blood pressure medicine")
New, voluntary recall issued for popular blood pressure medicine
Teva initiates U.S. recall of Topotecan metastatic ovarian cancer injection treatment - Drug Delivery Business
FDA recalls blood pressure medicine due to potential cancer risk
Drugs recalled after erectile dysfunction medication mixed with antidepressant in packaging 'mix-up' | NewsNation
Blood Pressure Medicine Is Recalled - The New York Times
RECALL ALERT: FDA Adds to List of Recalled Blood Pressure Drugs - The Diabetes Site News
Teva Pharmaceutical Industries: Teva to recall certain blood pressure medicine in U.S., Health News, ET HealthWorld
Teva Expands Recall of Blood Pressure Medication Due to Cancer Concerns
Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules | DAIC
Common blood pressure drug recalled over cancer-causing chemical fears | The US Sun
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
